Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study. [PDF]
Abosheaishaa H +9 more
europepmc +1 more source
Long-term clinical outcomes of carvedilol versus nebivolol in patients with ST-segment elevation myocardial infarction treated with second-generation drug-eluting stents: insights from a Korean nationwide multicenter prospective registry. [PDF]
Ahn J +9 more
europepmc +1 more source
Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study. [PDF]
Song BG +5 more
europepmc +1 more source
Response to Commentary on "Impact of Disease-Specific Treatment and NSBBs on Risk of PVT in Cirrhotic Patients With HCV or PBC". [PDF]
Gonzalez HC +10 more
europepmc +1 more source
Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study. [PDF]
Tarek M +4 more
europepmc +1 more source
Carvedilol is a non selective beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade (Strein et al., 1987, McTavish et al., 1993).
Hantson, Philippe +3 more
core
Subjective symptoms are associated with anxiety in patients with rosacea: a cross-sectional study. [PDF]
Huang Y +5 more
europepmc +1 more source
Carvedilol triggers ferroptosis in hepatic stellate cells via the ATF4/SAT1 axis promoting spermidine depletion to ameliorate liver fibrosis. [PDF]
Xia Y +5 more
europepmc +1 more source
Low-intensity pulsed ultrasound-mediated nose-to-brain co-delivery of β-blockers and aPD-L1 enhances glioblastoma immunotherapy. [PDF]
Dong L +20 more
europepmc +1 more source
Beta Blocker Toxicity at Therapeutic Doses: A Look Into Carvedilol Use in the Elderly. [PDF]
Amo-Tachie S.
europepmc +1 more source

